Cellworks

Founded in 2005 and headquartered in San Francisco, Cellworks has developed a sophisticated computational biology platform that simulates disease networks to predict therapy responses. The company serves both pharmaceutical clients (through its Precision Pharma offerings) and clinicians/patients (through its Personalized Therapy Decision Support products like SINGULA™ and VENTURA™). Its approach aims to de-risk drug development, optimize clinical trial design, and provide actionable treatment recommendations for refractory cancer patients by evaluating over 20 million potential drug combinations against a patient's unique molecular profile.

A proprietary Biosimulation Platform built on a mechanistic Computational Biology Model (CBM) of 6,000+ genes and 600,000+ molecular interactions. It uses patient multi-omic data to create Personalized Disease Models and runs in silico simulations to predict responses to over 350 drugs and 20+ million combinations, leveraging both mechanistic biology and AI/ML (Mechanistic Learning).

Cellworks competes in the computational drug discovery and therapy decision support space with pure-play AI biotechs (e.g., Exscientia, Recursion), large diagnostic companies expanding into therapy selection (e.g., Foundation Medicine, Tempus), and other simulation-focused firms. Its emphasis on mechanistic biology over purely data-driven AI is a key differentiator.